CERVICAL ADENOCARCINOMA
Clinical trials for CERVICAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CERVICAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for CERVICAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cancer drug enters first human trials for Tough-to-Treat tumors
Disease control Recruiting nowThis is the first study in humans testing a new cancer drug called AVA6103. The trial aims to find a safe dose and see if the drug shows early signs of helping patients with advanced solid tumors that have spread or cannot be removed by surgery. It will enroll adults with specifi…
Matched conditions: CERVICAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Avacta Life Sciences Ltd • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New hope for Tough-to-Treat cervical cancer
Disease control Recruiting nowThis study is testing a new combination of three drugs for women with a specific, hard-to-treat form of cervical cancer that has spread, come back, or hasn't responded to prior treatment. The goal is to see if this combination can shrink tumors and control the disease. It is for …
Matched conditions: CERVICAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
New 'Tumor-Seeking' radiation drug enters human trials for tough cancers
Disease control Recruiting nowThis study is testing a new type of cancer drug that delivers radiation directly to tumors by targeting a protein called Nectin-4. It aims to find a safe and effective dose for patients with advanced solid cancers who have already tried other treatments. The trial will first dete…
Matched conditions: CERVICAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC